Intraoperative radiotherapy for the treatment of thyroid cancer: a pilot study

Yi, Pei Qiang; Nie, Fang; Fan, You Ben; Wang, Yu; Hu, Chengfang; Guo, Xinying; Fei, Jie

doi:10.18632/oncotarget.12901

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the heterogeneity of the population included in these studies, large variations were observed in the outcomes, primarily coming from the studies using IOERT. Reported acute and late toxicity rates included wound infection ( n = 20, 9.9%) [ 38 ], vascular [transient ischemic attack (TIA), carotid blowout, cardiac ischaemic events] ( n = 23, 11.3%) [ 38 ], pain needing opiates ( n = 16, 13.3%) [ 34 ], osteoradionecrosis ( n = 4, 17.4%) [ 32 ] and mild nausea/vomiting (55.6%) [ 53 ].…”

Section: Heterogenous Studiesmentioning

confidence: 99%

“…Acute toxicities reported were wound infection/dehiscence in 1.6%–54% of patients [ 8 , 10 , 14 , 16 , 18 , 19 , 22 , 27 , 34 , 36 – 39 , 41 , 48 , 51 – 53 , 55 , 59 ], necrosis or flap failure in 0.7%–23% [ 14 , 16 , 18 , 23 , 26 , 28 – 30 , 38 , 39 , 52 , 55 , 59 ], osteonecrosis in 1.1%–8% [ 20 , 22 , 36 , 38 , 39 , 41 , 44 , 45 , 50 ], fistula in 1.5%–20% [ 8 , 10 , 14 , 16 , 18 – 20 , 24 – 26 , 30 , 31 , 33 , 34 , 37 – 39 , 41 , 44 , 46 , 52 , 53 , 59 ], trismus in 4.5%–24.6% [ 24 , 25 , 37 ], skin/mucosal complications in 2.3%–100% [ 8 , 10 , 14 – 16 , 24 , …”

Section: Heterogenous Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of intraoperative radiation therapy for head and neck cancer

Villafuerte¹,

Ylanan²,

Wong³

et al. 2022

ecancer

View full text Add to dashboard Cite

Multidisciplinary treatments with surgery, radiation therapy, and chemotherapy are the cornerstones in the management of locally advanced head and neck malignancies. In most cases, radiation is delivered via external beam radiation therapy (EBRT). Intraoperative radiation therapy (IORT), on the other hand, is the delivery of precise doses of radiation to selected target volumes within the exposed surgical field while at the operating room. Most studies on its use on head and neck cancers are limited to single-institutional retrospective case series. We performed a systematic review to consolidate the existing literature on IORT for head and neck malignancies. Fifty-two studies representing a mixed population of 2,389 patients were included in this review. IORT via electrons (intraoperative electron radiation therapy), brachytherapy (intraoperative high dose-rate brachytherapy) or photons was administered in numerous settings, but most commonly as part of a reirradiation regimen following salvage surgery for recurrent tumours. Often, additional EBRT was also planned postoperatively. This review illustrates that IORT is a promising treatment modality in head and neck cancer. Multiple single-institutional studies spanning several decades have demonstrated benefit in terms of local control with reasonable toxicity. However, randomised trials comparing it with current standards of care are still needed.

show abstract

Section: Heterogenous Studiesmentioning

confidence: 99%

Section: Heterogenous Studiesmentioning

confidence: 99%

Systematic review of intraoperative radiation therapy for head and neck cancer

Villafuerte¹,

Ylanan²,

Wong³

et al. 2022

ecancer

View full text Add to dashboard Cite

show abstract

“… 80 , 81 , 85 Intraoperative radiotherapy (IORT) permits higher radiation doses without harming healthy tissue but this has not yet been investigated in DTC. 86 …”

Section: External Beam Radiation Therapymentioning

confidence: 99%

Advancements in the treatment of differentiated thyroid cancer

Stewart

Kuo

2021

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Derived from follicular epithelial cells, differentiated thyroid cancer (DTC) accounts for the majority of thyroid malignancies. The threefold increase in DTC incidence over the last three decades has been largely attributed to advancements in detection of papillary thyroid microcarcinomas. Efforts to address the issue of overtreatment have notably included the reclassification of encapsulated follicular variant papillary thyroid cancers (EFVPTC) to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). In the last 5 years, the overall management approach for this relatively indolent cancer has become less aggressive. Although surgery and radioiodine ablation remain the mainstay of DTC therapy, the role of active surveillance is being explored. Furthermore, the most recent American Thyroid Association (ATA) guidelines offer flexibility between lobectomy and total thyroidectomy for thyroid nodules between 1 cm and 4 cm in the absence of extrathyroidal extension or nodal disease. As our understanding of the natural history and molecular underpinnings of DTC evolves, so might our approach to managing low-risk patients, obviating the need for invasive intervention. Simultaneously, advances in interventional and systemic therapies have greatly expanded treatment options for high-risk surgical candidates and patients with widespread disease, and continue to be areas of active investigation. Continued research efforts are essential to improve our ability to offer effective individualized therapy to patients at all disease stages and to reduce the incidence of recurrent and progressive disease.

show abstract